The New York high risk project to the Hillside recognition and prevention (RAP) program
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The sudden interest in initiating treatment before the onset of psychosis (i.e., during the prodromal stage of schizophrenia) has failed to integrate the earlier work on prediction generated by more traditional high‐risk studies. Genetic high‐risk research has most typically focused on the long‐term, prospective study of children of parents with schizophrenia. In this paper, it will be argued that high‐risk research can make at least two major contributions to prevention programs. First, previous findings can guide identification of risk factors and provide clues about causality, thus highlighting which pre‐morbid deficits should be treatment targets. For example, as discussed here, data from the New York High Risk Project points to impaired attention as a highly promising candidate risk factor, with a possible causal association with later‐emerging social deficits. Second, the high‐risk approach can provide a framework for establishing the predictive validity of prodromal clinical indicators and for understanding the nature of the schizophrenia prodrome. Preliminary findings from the Hillside Recognition and Prevention (RAP) program, integrating high‐risk methodology with an early intervention strategy, indicate that the prodrome is a developmentally complex phase of schizophrenia. In particular, a cluster of early features—including cognitive, academic, and social impairments, along with odd/disorganized behaviors—appear to anticipate positive symptoms and may constitute a core risk profile. Preliminary RAP treatment findings also suggest that medications other than anti‐psychotics may be effective for treating early prodromal symptoms, challenging the widely held hypothesis that anti‐psychotics should always be the first line preventive treatment. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kraemer, H. C., Stice, E., Kazdin, A., Offord, D., & Kupfer, D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.848 · Cited by 1,712
The Prodromal Phase of First-episode Psychosis: Past and Current Conceptualizations
Yung, A. R., & McGorry, P. D. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.353 · Cited by 1,168
Cornblatt, B. A., Lenzenweger, M. F., & Erlenmeyer-Kimling, L. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90188-1 · Cited by 399
Self-citation
Cited by
McNamara, R. K., & Carlson, S. E. (2006) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.07.010 · Cited by 545
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Seidman, L. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.66 · Cited by 409
Koutsouleris, N., Meisenzahl, E. M., Davatzikos, C., Bottlender, R., Frodl, T., Scheuerecker, J., Schmitt, G., Zetzsche, T., Decker, P., Reiser, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.62 · Cited by 406
Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia
Lencz, T., Smith, C. W., McLaughlin, D., Auther, A., Nakayama, E., Hovey, L., & Cornblatt, B. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.005 · Cited by 402
Self-citation
Metadata
- Authors
- Cornblatt, B. A.
- Venue
- American Journal of Medical Genetics
- Publisher
- Wiley
- Published
- 2002-08-30
- Volume
- 114
- Issue
- 8
- Pages
- 956-966
- ISSN
- 0148-7299 (ISSN-L)
- 1096-8628
- OpenAlex
- W2092577043
- Cited by
- 125
- References
- 3
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.